<DOC>
	<DOCNO>NCT00075517</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine docetaxel , use different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together docetaxel work treat patient inoperable stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Docetaxel Treating Patients With Inoperable Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient inoperable stage IIIB IV non-small cell lung cancer treat gemcitabine docetaxel . Secondary - Determine progression-free overall survival patient treat regimen . - Determine tolerance profile regimen patient . - Determine quality life patient treat regimen . OUTLINE : This nonrandomized , multicenter study . Patients receive docetaxel IV 1 hour gemcitabine IV 2 hour day 1 . Treatment repeat every 15 day 12 course absence disease progression unacceptable toxicity . Quality life assess baseline , course 6 12 , every 3 month thereafter . Patients follow every 3 month . PROJECTED ACCRUAL : A total 42 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer 1 follow histologic subtypes : Epidermoid carcinoma Large cell carcinoma Adenocarcinoma Stage IIIB ( T4 , N , M0 OR T , N3 , M0 ) OR Stage IV disease Inoperable disease Measurable disease At least 1 unidimensionally measurable lesion least 20 mm conventional technique OR least 10 mm spiral CT scan No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 75 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Platelet count least 100,000/mm^3 Absolute neutrophil count least 2,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin great normal Transaminases great 1.5 time normal Alkaline phosphatase great 2.5 time normal Renal Creatinine great 2.3 mg/dL Cardiovascular No uncontrolled cardiac insufficiency Other Not pregnant nursing Fertile patient must use effective contraception 6 month study therapy No uncontrolled infection No prior malignancy except curatively treat basal cell skin cancer carcinoma situ cervix No grade 3 4 brain disorder No intolerance polysorbate 80 cortisone PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy , include taxanes gemcitabine No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy 20 % bone marrow No prior radiotherapy lung cancer At least 4 week since prior radiotherapy recover Surgery No prior surgery lung cancer Other More 30 day since prior clinical trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>